Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Patheon acquires Roche's APIs manufacturing site in US

It will provide Patheon with a major APIs operation in the US capable of supporting products from clinical scale to commercial manufacturing

BS B2B Bureau  |  South Carolina (USA) 

Roche's Florence facility in US acquired by Patheon
Roche's Florence facility in US acquired by Patheon

NV, a global provider of high-quality drug development and delivery solutions to the and biopharma sectors, has acquired Roche’s active ingredients (APIs) manufacturing facility in Florence, South Carolina (USA). 

Under the terms of the purchase agreement, will acquire the site for an immaterial sum, plus the cost of associated inventory and spare parts. has also entered into a multi-year supply arrangement with Roche. expects the supply agreement to help defray the costs associated with running the site for the next few years while it adds new client work into the facility. Over time, expects the Florence facility to have a similar financial profile to its other sites in its drug substance segment.

will acquire the 300,000 sq ft facility with manufacturing capacity for ranging from development to manufacturing services. With the addition of this site, the company expands its capacity for manufacturing highly potent compounds, and adds capabilities to support solid-state chemistry, micronisation, and eventually, commercial spray drying.

“As the only end-to-end provider of pharma development and manufacturing services, is uniquely positioned to integrate this new site into our global network and quickly leverage the capabilities with existing and new clients. The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals,” said James Mullen, CEO of Patheon.

The site features reactors ranging from 50-11,000 litres producing multiple products simultaneously, fully compliant with all applicable regulations, such as (current good manufacturing practices) safety and environmental standards. It will provide with a major US operation capable of supporting products from clinical scale to commercial manufacturing and further enhances its scientific and technical expertise.

RECOMMENDED FOR YOU

Patheon acquires Roche's APIs manufacturing site in US

It will provide Patheon with a major APIs operation in the US capable of supporting products from clinical scale to commercial manufacturing

It will provide Patheon with a major APIs operation in the US capable of supporting products from clinical scale to commercial manufacturing
NV, a global provider of high-quality drug development and delivery solutions to the and biopharma sectors, has acquired Roche’s active ingredients (APIs) manufacturing facility in Florence, South Carolina (USA). 

Under the terms of the purchase agreement, will acquire the site for an immaterial sum, plus the cost of associated inventory and spare parts. has also entered into a multi-year supply arrangement with Roche. expects the supply agreement to help defray the costs associated with running the site for the next few years while it adds new client work into the facility. Over time, expects the Florence facility to have a similar financial profile to its other sites in its drug substance segment.

will acquire the 300,000 sq ft facility with manufacturing capacity for ranging from development to manufacturing services. With the addition of this site, the company expands its capacity for manufacturing highly potent compounds, and adds capabilities to support solid-state chemistry, micronisation, and eventually, commercial spray drying.

“As the only end-to-end provider of pharma development and manufacturing services, is uniquely positioned to integrate this new site into our global network and quickly leverage the capabilities with existing and new clients. The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals,” said James Mullen, CEO of Patheon.

The site features reactors ranging from 50-11,000 litres producing multiple products simultaneously, fully compliant with all applicable regulations, such as (current good manufacturing practices) safety and environmental standards. It will provide with a major US operation capable of supporting products from clinical scale to commercial manufacturing and further enhances its scientific and technical expertise.
image
Business Standard
177 22

Patheon acquires Roche's APIs manufacturing site in US

It will provide Patheon with a major APIs operation in the US capable of supporting products from clinical scale to commercial manufacturing

NV, a global provider of high-quality drug development and delivery solutions to the and biopharma sectors, has acquired Roche’s active ingredients (APIs) manufacturing facility in Florence, South Carolina (USA). 

Under the terms of the purchase agreement, will acquire the site for an immaterial sum, plus the cost of associated inventory and spare parts. has also entered into a multi-year supply arrangement with Roche. expects the supply agreement to help defray the costs associated with running the site for the next few years while it adds new client work into the facility. Over time, expects the Florence facility to have a similar financial profile to its other sites in its drug substance segment.

will acquire the 300,000 sq ft facility with manufacturing capacity for ranging from development to manufacturing services. With the addition of this site, the company expands its capacity for manufacturing highly potent compounds, and adds capabilities to support solid-state chemistry, micronisation, and eventually, commercial spray drying.

“As the only end-to-end provider of pharma development and manufacturing services, is uniquely positioned to integrate this new site into our global network and quickly leverage the capabilities with existing and new clients. The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals,” said James Mullen, CEO of Patheon.

The site features reactors ranging from 50-11,000 litres producing multiple products simultaneously, fully compliant with all applicable regulations, such as (current good manufacturing practices) safety and environmental standards. It will provide with a major US operation capable of supporting products from clinical scale to commercial manufacturing and further enhances its scientific and technical expertise.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard